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Abstract
Objectives and hypothesis To establish the reliability and va-
lidity of the Dutch version of the Pelvic Organ Prolapse/
Urinary Incontinence Sexual Questionnaire (PISQ-12) in
women with pelvic floor dysfunction.
Methods The PISQ-12 was translated into Dutch following a
standardized translation process. A group of 124 women in-
volved in a heterosexual relationship who had had symptoms
of urinary incontinence, fecal incontinence and/or pelvic or-
gan prolapse for at least 3 months were eligible for inclusion.
A reference group was used for assessment of discriminative
ability. Data were analyzed for internal consistency, reproduc-
ibility, construct validity, responsiveness, and interpretability.
An alteration was made to item 12 and was corrected for
during the analysis.
Results The patient group comprised 70 of the 124 eligible
women, and the reference group comprised 208 women from
a panel representative of the Dutch female population. The
Dutch PISQ-12 showed an adequate internal consistency with
a Cronbach’s alpha of 0.57 – 0.69, increasing with correction
for item 12 to 0.69 – 0.75, for the reference and patient group,
respectively. Scores in the patient group were lower (32.6±
6.9) than in the reference group (36.3±4.8; p=0.0001), indi-
cating a lower sexual function in the patient group and good
discriminative ability. Reproducibility was excellent with an
intraclass correlation coefficient for agreement of 0.93
(0.88 – 0.96). A positive correlation was found with the Short
Form-12 Health Survey (SF-12) measure representing good
criterion validity. Due to the small number of patients who had
received treatment at the 6-month follow-up, no significant
responsiveness could be established.
Conclusions This study showed that the Dutch version of the
PISQ-12 has good validity and reliability. The PISQ-12 will
enable Dutch physicians to evaluate sexual dysfunction in
women with pelvic floor disorders.
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Introduction
Women who suffer from pelvic floor disorders (PFD) gener-
ally experience a reduced quality of life [1]. PFD includes
urinary incontinence (UI), pelvic organ prolapse (POP) and/
or fecal incontinence (FI). The prevalence of PFD in adult
women has been estimated to be 23.7 % and increases with
age up to 49.7 % in women aged 80 years or older [2]. Several
studies have shown that women suffering from UI and POP
experience a deterioration in sexual function [3–5], and FI has
also been associated with poorer sexual function [6]. Given
the number of women suffering from PFD, it is important to
evaluate their sexual function. Questionnaires can be used to
assess the necessity for treatment of sexual dysfunction, and to
determine treatment effectiveness.
The Pelvic Organ Prolapse/Urinary Incontinence Sexual
Questionnaire (PISQ-12) is a validated condition-specific
quality of life questionnaire [7]. The International Continence
Society recommends this questionnaire (with grade A) to
* Lisette A. ‘t Hoen
l.thoen@erasmusmc.nl
1 Department of Urology, Erasmus Medical Center, Room Na-1724,
PO Box 2040, 3000, CA Rotterdam, The Netherlands
2 Department of Obstetrics and Gynecology, Erasmus Medical Center,
Rotterdam, The Netherlands
3 Department of Public Health, Erasmus Medical Center,
Rotterdam, The Netherlands
Int Urogynecol J (2015) 26:1293–1303
DOI 10.1007/s00192-015-2692-y
assess sexual function with urinary symptoms [8]. In recent
years the PISQ-12 has been validated in different languages:
Arabic, Chinese, French, Persian, Portuguese, Swedish and
Turkish [9–15]. The increased awareness of sexual dysfunc-
tion in association with PFD strengthens the need for a vali-
dated Dutch measurement tool for sexual function [16]. A
recent study has used a Dutch translation of the PISQ-12 to
evaluate sexual function in the Dutch population [17]. How-
ever, this version was not validated and the results can there-
fore not be considered internationally compatible. The aim of
this study is to develop a validated Dutch version of the PISQ-
12 measure.
Materials and methods
This observational study was performed at a tertiary pelvic
floor center. It is part of a larger health-related quality of life
study, which was approved by the medical research ethics
committee (MEC-2008-376) [18, 19].
Study populations
Patient group
Women were eligible for inclusion if they spoke Dutch
fluently, were aged over 18 years, and in a heterosexual
relationship. Also, they needed to have been experiencing
symptoms of UI, POP stage 2 or higher and/or FI for at
least 3 months. Exclusion criteria consisted of dementia,
mental retardation, active malignant tumors, and no sexu-
al activity during the past 6 months. During a regular
outpatient visit all potentially eligible patients were in-
formed about the study, and invited to participate by their
treating physician. A patient information package contain-
ing the consent form and the first two sets of measures
were handed out. Patients were asked to fill in the ques-
tionnaires at three predetermined time-points (during the
inclusion visit, and at 1 week and 6 months after inclu-
sion), and to return the questionnaires by post directly
after completion. The patients’ educational levels were
determined and classified as Blower^ (primary school),
Bmiddle^ (high school), and Bhigher^ (college or univer-
sity). The final questionnaire contained an extra question
taken from the RAND 36-Item Health Survey (RAND 36-
HTI). Patients were asked to compare their current general
health status to their status 1 year ago [20]. No treatment
was initiated during the first week following inclusion.
Physicians and patients were unrestricted in the choice
of treatment given the observational character of this
study. For treatment evaluation we distinguished conser-
vative, pharmaceutical and surgical treatments.
Reference group
The reference group in this study was taken from an ISO-
certified (ISO 26362) panel of Dutch women 18 years of age
or older. This group was stratified for age, educational level
and residence to act as a representative group of the Dutch
female population. Beforehand, the presence of pelvic floor
symptoms in this group was unknown.
Questionnaire
The questionnaire consisted of two measures:
– The PISQ-12 is a short-form of the PISQ-31 measure
[21]. It is a condition-specific measure that evaluates
sexual function in heterosexual women who suffer
from UI and/or POP. The PISQ-12 measures three
domains: behavioral-emotive (items 1 – 4), physical
(items 5 – 9) and partner-related (items 10 – 12). It is
a self-administered questionnaire, and responses are
graded on a five-point Likert scale ranging from 0
(always) to 4 (never). Items 1 – 4 are reversely scored
and a total of 48 is the maximum score [22]; higher
scores indicate better sexual function. Up to two
missing responses are accepted. The total score sum
with missing values is calculated by multiplying the
number of items by the mean of the responses to the
items reported by that person. The PISQ-12 is report-
ed as a single sexual function score. It does not report
the separate domains [7].
– The Short Form-12 Health Survey (SF-12) consists of
two summary measures, physical component scores
(PCS-12) and mental component scores (MCS-12) [23].
It is the short-form of the SF-36 measure and is frequently
used as a gold standard for health-related quality of life
questionnaires [14, 10]. The SF-12 was distributed to the
patient group only.
Linguistic validation
The translation process of the PISQ-12 was performed
according to a standardized guideline [24]. First the En-
glish PISQ-12 was forward-translated by three indepen-
dent native Dutch speakers. Differences were discussed
and consensus was reached on the final version, which
was then backward-translated by a native English speak-
er. A face-to-face test with ten patients was performed,
and small textural changes were made accordingly with-
out the need to adapt the content, resulting in the final
Dutch version (Appendix).
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Measurement properties
The questionnaire was validated according to the following
measurement properties;
1. Content validity: the extent to which the questionnaire
measures the concepts of interest in the target population.
The correspondence between the questionnaire items and
clinical symptoms was subjectively assessed by the re-
searchers. Face validity was determined by the re-
searchers and a selected group of patients during linguistic
validation [25].
2. Internal consistency: the correlation between differ-
ent items in a questionnaire for the total and sub-
scale scores, i.e. do the questions measure the same
construct? A Cronbach’s alpha was calculated for
the total score and three subscale scores separately.
Internal consistency is considered good if the
Cronbach’s alpha was between 0.70 and 0.95 [25].
For study-related reasons we also calculated the
Cronbach’s alpha of the PISQ-12 minus item 12
for total score and the partner-related subscale
score.
3. Reproducibility: the degree to which scores on a question-
naire are similar in a stable person on repeated measure-
ments. This can be reported through reliability and agree-
ment [25].
1. Reliability considers the degree to which patients can
be differentiated from each other, despite measure-
ment error. The intraclass correlation coefficient
(ICC) for agreement was calculated to assess the
test–retest reliability. A value of at least 0.70 is the
minimum standard [26].
2. Agreement concerns the similarity in scores when
measured on separate occasions, i.e. the measurement
error. The limits of agreement (LOA) were reported
and equal the mean change in scores of repeated mea-
surements±1.96 × standard deviation (SD) of the
changes [27].
4. Criterion validity: the degree to which questionnaire
scores correlate with a gold standard. For the PISQ-12
no perfect gold standard exists. Therefore, criterion
validity was determined using the SF-12, a quality
of life measure resulting in physical and mental sum-
mary scores, which was also used in the Chinese val-
idation [10]. Spearman’s correlation was determined
with values ranging from −1 to +1. A stronger nega-
tive or positive correlation is found when values are
close to the extremes [25].
5. Construct validity: the extent to which hypotheses about
the scores of a questionnaire in relation to other measures
are valid. If at least 75 % of the predefined hypotheses are
correct, construct validity is considered adequate [25].
The predetermined hypotheses were:
1. Women with lower scores on the PCS-12 have lower
scores on the PISQ-12.
2. Women in the patient group will have lower PISQ-12
scores than women in the reference group.
3. PISQ-12 scores will increase after women have re-
ceived treatment.
6. Responsiveness: the extent to which a questionnaire is
able to detect clinically important changes over time. This
was calculated for all patients who had received treatment.
The RAND 36-HTI was used as an external criterion in
the determination of the area under the receiver operating
characteristic (ROC) curve (AUC) for the PISQ-12 mea-
surements. The AUC shows the ability of a questionnaire
to distinguish patients who have improved. An AUC of at
least 0.50 is considered adequate [25].
7. Interpretability: the degree to which a qualitative meaning
can be assigned to the quantitative questionnaire scores.
The minimal important change (MIC) is the minimal
change required to indicate a true clinically relevant im-
provement. The LOA should be smaller than the MIC
[25]. The anchor-based ROC approach was used to deter-
mine the MIC. The MIC is the optimal ROC cut-off point
and is defined as the value for which the sum of the pro-
portions formisclassifications ((1− sensitivity)+(1− spec-
ificity)) is smallest [28].
8. Floor and ceiling effects: if more than 15 % of the women
have received the lowest or highest possible score [25].
Floor and ceiling effects were assessed at the total and
subscale levels.
Statistical methods
To determine the sample size the quality criteria proposed by
Terwee et al. [25] were followed. These state that a sample
size of at least 50 patients is considered adequate to validate
the questionnaire in Dutch. For continuous data we report the
mean and standard deviation (SD). For categorical data we
report counts and percentages. To evaluate the differences
between the patient and reference group Student’s t test and
the chi-squared test were used for continuous and categorical
variables, respectively. One-way analysis of variance
(ANOVA) was used for the evaluation of more than two in-
dependent groups. A two-sided p value of <0.05 was consid-
ered significant. The anchor RAND 36-HTI was dichoto-
mized to Bimproved^ and Bnot improved^; Ba little better^
and Bmuch better^ were classified as Bimproved^, while
Bsame^, Ba little worse^ and Bmuch worse^ were classified
as Bnot improved^. Statistical analysis of the data was done
using SPSS version 21.0 (IBM Corp., Armonk, NY).
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Results
Of the 124 consecutive patients who were interested in
participation in the study, 100 were found to be eligible
and 70 of these patients consented to participate after
receiving further information. During analysis, data from
70 patients were available, and consisted of at least one
completed measure at one time-point (Fig. 1). The refer-
ence group consisted of 208 women who had responded
of 450 Dutch women contacted. Table 1 displays the
nature of PFD in the patient group. The women in the
reference group were younger than the women in the
patient group (45.1±14.2 years and 53.6±12.3 years,
respectively; p<0.001). There was also a significant dif-
ference in educational level, with an average higher level
of education in the reference group (p=0.004).
During the layout process of the PISQ-12 the answers to
item 12 were incorrectly altered from Bmuch less intense to
much more intense^ to Balways to never .^ This unfortunate
alteration resulted in suboptimal answer options. Therefore,
we calculated the total score without item 12 as well. The
reference group showed significant an overall higher scores
on the PISQ-12 measure than the patient group, indicating
better sexual function in this group. After correcting for the
altered item 12, the difference between the patient and refer-
ence group remained significant (Table 1).
Female patients interested in 
participation
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(n = 70 )
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Fig. 1 Flow chart showing the
inclusion process of the patient
group
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Measurement properties
1. Content validity: The content validity was determined to
be adequate by the researchers and the selected patient
group during the linguistic validation process.
2. Internal consistency: Table 2 shows that the PISQ-12 total
score had an adequate internal consistency in the patient
group, with a Cronbach’s alpha of 0.69. In the reference
group the internal consistency showed a moderate
Cronbach’s alpha of 0.57. The domain scales differed be-
tween the patient and reference groups from 0.37 – 0.85
and 0.13 – 0.72, respectively. In addition, we calculated
the Cronbach’s alpha without item 12. The PISQ-12
showed an adequate internal consistency of 0.75 and
0.69 for the patient and reference groups, respectively.
For the partner-related scale internal consistency im-
proved from 0.37 to 0.55 for the patient group, and from
0.13 to 0.49 for the reference group.
3. Reproducibility: A total of 62 patients completed the
questionnaires at baseline and the retest after a week
(Table 2). The average test–retest period was 6.8±
2.6 days. For the PISQ-12 ICC for agreement was
0.93 (range 0.88 – 0.96). This indicates adequate
reliability. The ICC for agreement remained ade-
quate after correction for item 12: 0.94 (range
0.90 – 0.96). Relating the LOA range (10.6) to the
total PISQ-12 score range (48) resulted in an ex-
pected measurement error of 22 %.
4. Criterion validity: The PISQ-12 scores showed pos-
itive correlations with the two summary scores of
the SF-12 (PCS-12 and MCS-12; Fig. 2). For the
PISQ-12 and PCS-12 adequate agreement was found
at baseline and the 6-month follow-up (Spearman’s
rho 0.41 and 0.34, respectively). The PISQ-12 and
MCS-12 showed only adequate agreement at base-
line (Spearman’s rho 0.32).
Table 1 Demographic and
clinical characteristics of the
study population (patient and
reference groups)
Patient group (n=70a) Reference group (n=208) p value
Age (years), mean±SD 53.6±12.3 45.1±14.2 <0.001d
Education, n (%)
Lower 21 (31) 60 (29) 0.004e
Middle 38 (57) 86 (41)
Higher 8 (12) 62 (30)









Baseline 32.7±7.0 36.3±4.7 0.001d
Baseline, minus item 12 30.7±7.1 34.8±5.1 0.01d
6 months (n=56) 33.5±6.5








a Unless stated otherwise
b Higher scores indicate better sexual function
c Every score higher than 50 indicates better quality of life, every score lower than 50 indicates poorer quality of
life
d Student’s t test
e Chi-squared test
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Table 2 Internal consistency and reproducibility. Cronbach’s alpha reflects the internal consistency for the total and subscale scores. The
reproducibility is presented in terms of intraclass correlation coefficient and limits of agreement
Internal consistency Reproducibility (n=62)














PISQ-12 total 0.69 0.57 32.6±7.1 33.0±7.1 0.93 (0.88 – 0.96) −0.32±2.71 −5.63 to 4.99
Minus item 12 0.75 0.69 30.7±7.3 31.0±7.3 0.94 (0.90 – 0.96) −0.32±2.52 −5.26 to 4.62
Behavioral emotive 0.85 0.72 9.58±3.86 9.68±3.69 0.90 (0.84 – 0.94) −0.05±1.45 −2.89 to 2.79
Physical 0.71 0.62 14.48±4.53 14.71±4.38 0.94 (0.90 – 0.96) −0.23±1.54 −3.25 to 2.79
Partner-related 0.37 0.13 8.58±2.27 8.63±2.31 0.80 (0.69 – 0.87) −0.05±1.67 −3.32 to 3.22
Minus item 12 0.55 0.49 6.66±1.80 6.71±2.00 0.85 (0.77 – 0.91) −0.05±1.03 −2.07 to 1.97
a Calculated as: y=mean(change)±1.96 × SD(change)
Fig. 2 Correlations between and PISQ-12 SF-12 scores to establish the
criterion validity. a PISQ-12 vs. PCS-12 at baseline (n=56; Spearman’s
rho 0.41; p=0.005). b PISQ-12 vs. PCS-12 at 6 months (n=46;
Spearman’s rho 0.34; p=0.02). c PISQ-12 vs. MCS-12 at baseline (n=
56; Spearman’s rho 0.32; p=0.03). d PISQ-12 vs. MCS-12 at 6 months
(n=46; Spearman’s rho 0.26; p=0.07)
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5. Construct validity: two of our three predefined hypotheses
were confirmed:
1. A significant correlation was found between the PCS-
12 score and the PISQ-12 score (Fig. 2).
2. Women in the patient group did indeed have lower
PISQ-12 scores than women in the reference group
(Table 1).
3. Women who received treatment did not show a sig-
nificant improvement in PISQ-12 score compared to
before treatment (Table 3).
6. Responsiveness: At the 6-month follow-up, 56 patients
completed the third round of questionnaires as shown in
Table 1. Of these patients, 27 had received treatment for
either UI, POP or FI. This treatment consisted of surgical
treatment in 15 patients (56 %), conservative treatment in
9 patients (33 %) and pharmaceutical treatment in 3 pa-
tients (11 %). Of these 27 patients, 24 answered the
RAND 36-HTI question. The AUC for the PISQ-12 in
this group was 0.69 (p=0.14, not significant; Table 3).
7. Interpretability: The MIC was −0.50 with a sensitivity of
0.89 and a specificity of 0.60 (Table 3). This corresponds
with 89 % correctly identified as improved and 60 % as
not improved. The MIC was inside the range of the LOA,
indicating that the change in score of −0.50 in treated
patients who have reported an improvement on the
RAND 36-HTI was not clinically relevant.
8. Floor and ceiling effects: The distribution of floor and
ceiling effects for the patient and reference groups is
shown in Table 4. No floor and ceiling effects were re-
ported in the patient group or the reference group for the
PISQ-12 total score. Furthermore, no floor and ceiling
effects were reported in the patient group on the scale
level. In the reference group, only a ceiling effect on the
physical scale was reported.
Discussion
In response to the growing need for a validated measure for
sexual dysfunction in women with PFD, the aim of this study
was to provide a validated Dutch version of the PISQ-12 mea-
sure. In women with PFD significantly lower PISQ-12 scores
were observed than in the reference group representing the
Dutch female population. This indicates poorer sexual func-
tion in the patient group, as expected, confirming the discrim-
inative ability of the PISQ-12 measure. It also stresses the
need to consider treatment options for sexual dysfunction in
addition to treatment options for PFD alone.
The study showed that the Dutch version of the PISQ-12 has
moderate internal consistency. Cronbach’s alpha was 0.69 in
the patient group and 0.57 in the reference group. Other studies
validating the PISQ-12 in different languages have shown
higher Cronbach’s alpha values, ranging from 0.71 to 0.79
[15, 13, 14, 10]. The lower value found in this study originated
from the partner-related item scale, probably due to the alter-
ation of item 12. A Cronbach’s alpha for the partner-related
scale of 0.37 was found in the patient group, in contrast to
0.13 in the reference group when no adjustment for item 12
was performed. With correction for item 12, Cronbach’s alpha
scores for both the total score and the partner-related score
increased to values comparable to those found for the earlier
translated PISQ-12 versions. The internal consistency of the
PISQ-12 then showed an adequate value of 0.75 for the patient
group and 0.69 for the reference group. The big discrepancy
found between the patient and reference group at the scale level
was also resolved with the correction. This suggests that the
incorrect answer options for item 12 caused the lower values
before correction. Overall, the PISQ-12 showed an adequate
consistency for the remaining 11 items.
The internal consistency of the partner-related scalewas lower
than that of the total score and both the behavioral-emotive scale
and the physical scale, even after correction for item 12. This was
also found in previous translations of the PISQ-12 [15, 10]. It
Table 3 PISQ-12 scores in patients who received treatment and their
corresponding RAND-36 response reflect responsiveness and interpret-
ability of the PISQ-12. The RAND-36 functions as an anchor
Number (%) (n=24a) PISQ-12 scoreb
RAND-36 health transition item
Much worse/a little worse 5 (21) 2.60±8.38
Same 10 (42) −0.10±5.97
A little better 5 (21) 2.20±3.27
Much better 4 (17) 5.00±4.97
Area under the ROC curve 0.69
p-value 0.14
Minimal important change −0.50
Sensitivity 0.89
Specificity 0.60
Data presented are number (%) or mean change±SD change between
baseline and 6-month follow-up
a Responsiveness reported only for the 24 patients who received treatment
b Positive scores indicate an improvement in sexual function
Table 4 Floor and ceiling effects at baseline for the patient and
reference groups
PISQ-12 Patient group (n=70) Reference group (n=208)
Floor Ceiling Floor Ceiling
Total score 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Behavioral emotive 3 (4 %) 0 (0 %) 1 (0.5 %) 2 (1 %)
Physical 0 (0 %) 10 (14 %) 0 (0 %) 53 (25 %)
Partner-related 0 (0 %) 7 (10 %) 0 (0 %) 13 (6 %)
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should be noted that the partner-related scale evaluates the phys-
ical sexual function related to the partner. However, even though
sexual function is related to the partner, a poorer physical sexual
function in the partner will not automatically result in a similar
sexual dysfunction in the woman. A lower partner-related scale
score does not need to be correlated with the behavioral-emotive
and physical scale scores.
The reproducibility for the Dutch PISQ-12 in terms of the
test–retest scores was excellent. The ICC for agreement was
0.93, comparable to that of the Swedish PISQ-12 [14],
confirming the reproducibility of this measure. With correc-
tion for item 12 the reliability remained stable, as expected,
since patients received the same version of the measure at both
time-points. The good ICC value enables the use of the PISQ-
12 as a measure for distinguishing the severity of sexual dys-
function between patients.
The criterion validity of a questionnaire is preferably deter-
mined by the degree of its correlation the gold standard. Since
no gold standard is available to determine sexual dysfunction
in women with PFD we chose to use the SF-12 [23] to assess
the criterion validity of the PISQ-12. The SF-12 is a common-
ly used generic measure for health-related quality of life and
was also used in the Chinese validation study of the PISQ-12
[10]. We found a positive correlation between sexual dysfunc-
tion as assessed with the PISQ-12 and both summary scores of
the SF-12 at baseline. However, at the 6-month follow-up the
PISQ-12 showed a significant correlation with the PCS-12,
but not with the MCS-12. This weakened correlation at
follow-up could potentially be explained by the fact that the
group of patients was smaller at 6 months. It is also possible
that the SF-12 was not the right choice to assess the criterion
validity because the SF-12 is a generic measure: changes in
quality of life unrelated to sexual dysfunction might have in-
fluenced the SF-12 score without influencing the PISQ-12
score (criterion contamination). We are thus unable to con-
clude that the PISQ-12 has a good criterion validity using
the SF-12. Therefore, we recommend the use of a larger pa-
tient group to determine the criterion validity of the PISQ-12.
The responsiveness and interpretability reported were not
adequate. Of the 35 patients who did receive treatment during
the 6-month follow-up, only 24 completed the third question-
naire including RAND 36-HTI. This small number of patients
could explain why the AUC and MIC were not significant.
Furthermore, the studywas conducted at a tertiary center, where
women might present with more severe symptoms of PFD.
Treatment options might therefore be more limited, which
could explain the only slight overall improvement of PISQ-12
scores after treatment. This probably also contributed to the
inability to confirm hypothesis 3 for the construct validity. In
addition, the anchor used for responsiveness evaluation, the
RAND 36-HTI, solely addresses one aspect of general health,
while sexual function is multifactorial. It might therefore not
provide an adequate comparison for this specific evaluation.
No floor or ceiling effects were found for the total score of
the PISQ-12 for the patient group or the reference group. The
complexity of symptoms of PFD could have contributed to the
lack of floor and ceiling effects in the patient group. In the
reference group ceiling effects were found only on the phys-
ical subscale. This has previously also been demonstrated in
patients [29]. After treatment the physical subscale showed
ceiling effects, while the other subscales did not.
The strength of this study was the use of the quality criteria
for the evaluation of the measurement properties tested, as pro-
posed by Terwee et al. [25]. Also, the use of a reference group
enabled clarification of differences in sexual function between
patients with PFD and a reference population. There are some
limitations to this study. First, item 12 was altered during the
layout process. In our opinion, errors can (and will) always
occur. If an error does occur, we think it best to acknowledge
it and try to correct for it in the analysis. Second, the small
number of patients during our 6-month follow-up made it dif-
ficult to properly assess the responsiveness of the Dutch PISQ-
12. Third, the PISQ-12 can only be used in sexually active
women. Consequently, an assessment of sexual dysfunction in
sexually inactive women cannot be performed. The PISQ-IR is
a new questionnaire that does take sexual function and activity
or inactivity into account [30]. Therefore, the PISQ-IR can be
used in all patients presenting with symptoms of PFD. Howev-
er, currently no validated Dutch version is available. The actual
use of the Dutch PISQ-12 might affect treatment in sexually
active women. It would be worthwhile to evaluate the impact of
the use of the Dutch PISQ-12 in clinical practice.
In conclusion, this Dutch version of PISQ-12 was tested
following well-established guidelines on measurement prop-
erties. It was demonstrated to have adequate validity and re-
producibility, especially after correction for item 12 on the
partner-related scale. The use of this measure in clinical prac-
tice will enable Dutch physicians to assess the impact of sex-
ual dysfunction on women with PFD who are sexually active.
It is recommended that responsiveness be determined in a
larger group of patients.
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